Literature DB >> 31503148

Referral Center Experience With Nonpalpable Contraceptive Implant Removals.

Melissa C Matulich1, Melissa J Chen, Natasha R Schimmoeller, Jennifer K Hsia, Suji Uhm, Machelle D Wilson, Mitchell D Creinin.   

Abstract

OBJECTIVE: To describe our experience with office removal of nonpalpable contraceptive implants at our referral center.
METHODS: We performed a retrospective cohort study by reviewing the charts of patients referred to our family planning specialty center for nonpalpable or complex contraceptive implant removal from January 2015 through December 2018. We localized nonpalpable implants using high-frequency ultrasonography and skin mapping in radiology, followed by attempted removal in the office using local anesthesia and a modified vasectomy clamp. We abstracted information on demographics, implant location, and outcomes.
RESULTS: Of 61 referrals, 55 patients attended their scheduled appointments. Seven patients had palpable implants; six elected removal. The other 48 patients had ultrasound localization, which identified 47 (98%) of the implants; the remaining patient had successful localization with computed tomography imaging. Nonpalpable implants were suprafascial (n=22), subfascial (n=25) and intrafascial (n=1); four of these patients opted to delay removal. Of 50 attempted office removals, all palpable (n=6), all nonpalpable suprafascial (n=21 [100%, 95% CI 83-100%]), and 19 out of 23 (83%, 95% CI 67-98%) subfascial implants were successful. Three of the four patients with failed subfascial implant office removal had successful operating room removal with a collaborative orthopedic surgeon; the other patient sought removal elsewhere. Transient postprocedure neuropathic complaints were noted in 7 out of 23 (30%, 95% CI 12-49%) subfascial and 1 out of 21 (5%, 95% CI 0-13%) suprafascial removals (P=.048). Nonpalpable implants were more likely to be subfascial in nonobese patients (24/34, 71%) as compared with obese (1/13, 8%) patients (P<.001). Seven (28%) of the 25 subfascially located implants had been inserted during a removal-reinsertion procedure through the same incision.
CONCLUSION: Most nonpalpable contraceptive implants can be removed in the office by an experienced subspecialty health care provider after ultrasound localization. Some patients may experience transient postprocedure neuropathic pain. Nonpalpable implants in thinner women are more likely to be in a subfascial location.

Entities:  

Mesh:

Year:  2019        PMID: 31503148      PMCID: PMC6768758          DOI: 10.1097/AOG.0000000000003457

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  18 in total

1.  UK provision for removal of non-palpable contraceptive implants.

Authors:  Diana Mansour
Journal:  J Fam Plann Reprod Health Care       Date:  2009-01

2.  Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.

Authors:  David L Eisenberg; Courtney A Schreiber; David K Turok; Stephanie B Teal; Carolyn L Westhoff; Mitchell D Creinin
Journal:  Contraception       Date:  2015-04-28       Impact factor: 3.375

3.  Removal of non-palpable etonogestrel implants.

Authors:  Diana Mansour; Martyn Walling; Derek Glenn; Christian Egarter; Olivier Graesslin; Josef Herbst; Ian S Fraser
Journal:  J Fam Plann Reprod Health Care       Date:  2008-04

4.  Hormone-releasing contraceptive implants: our experience of complex removals using preoperative ultrasound.

Authors:  S R Vollans; A Grainger; P O'Connor; D Limb
Journal:  Contraception       Date:  2015-04-15       Impact factor: 3.375

5.  Removal of a Nexplanon implant located in the biceps muscle using a combination of ultrasound and fluoroscopy guidance.

Authors:  Maryam Guiahi; Kristina Tocce; Stephanie Teal; Tyler Green; Paul Rochon
Journal:  Contraception       Date:  2014-06-27       Impact factor: 3.375

6.  The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience.

Authors:  Mitchell D Creinin; Andrew M Kaunitz; Philip D Darney; Lisa Schwartz; Tonja Hampton; Keith Gordon; Hans Rekers
Journal:  Contraception       Date:  2016-07-21       Impact factor: 3.375

7.  Location and removal of non-palpable Implanon implants with the aid of ultrasound guidance.

Authors:  Madan Singh; Diana Mansour; David Richardson
Journal:  J Fam Plann Reprod Health Care       Date:  2006-07

8.  Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.

Authors:  Klaas Heinemann; Suzanne Reed; Sabine Moehner; Thai Do Minh
Journal:  Contraception       Date:  2015-01-16       Impact factor: 3.375

Review 9.  Management and localization strategies for the nonpalpable Implanon rod.

Authors:  Lee P Shulman; Helena Gabriel
Journal:  Contraception       Date:  2005-12-27       Impact factor: 3.375

10.  Removal of a Nonpalpable Etonogestrel Implant With Preprocedure Ultrasonography and Modified Vasectomy Clamp.

Authors:  Melissa J Chen; Mitchell D Creinin
Journal:  Obstet Gynecol       Date:  2015-11       Impact factor: 7.661

View more
  4 in total

1.  Difficult etonogestrel implant removals in South Africa: A review of 74 referred cases.

Authors:  Gregory Petro; Trevi Spence; Malika Patel; Alida M Gertz; Chelsea Morroni
Journal:  Contraception       Date:  2020-04-24       Impact factor: 3.375

2.  Minimally invasive removal of deep contraceptive implants under continuous ultrasound guidance is effective, quick, and safe.

Authors:  Thibaut Jacques; Charlotte Brienne; Simon Henry; Hortense Baffet; Géraldine Giraudet; Xavier Demondion; Anne Cotten
Journal:  Eur Radiol       Date:  2021-10-14       Impact factor: 7.034

3.  Characteristics of Patients Requiring Surgical Removal of Subdermal Contraceptive Implants: A Case-Control Study.

Authors:  Leila Katabi; Erica Stevens; Mona Ascha; Kavita Arora
Journal:  Open Access J Contracept       Date:  2022-08-08

Review 4.  Safety and Benefits of Contraceptives Implants: A Systematic Review.

Authors:  Morena Luigia Rocca; Anna Rita Palumbo; Federica Visconti; Costantino Di Carlo
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.